Psoriatic Arthritis

MAUI, Hawaii — A novel TYK2 inhibitor may provide clinicians with another treatment option along the janus kinase pathway in patients with severe psoriasis, according to a presentation at the 2020 Rheumatology Winter Clinical Symposium.

The use of biologic therapy to treat psoriasis and psoriatic arthritis has increased over time along with the use of systemic corticosteroids, according to a letter published in the Journal of the American Academy of Dermatology.

The 2020 Rheumatology Winter Clinical Symposium will feature presentations intended to foster active discussion between those on the dais and those in attendance. The meeting, which is in its 13th year, will take place February 12 to 15, at the Wailea Beach Marriott in Maui, Hawaii.

A significant proportion of patients with psoriatic arthritis experience a prodromal period, as early as 5 years prior to diagnosis, characterized by musculoskeletal symptoms and an increase in health care use and costs, according to data published in Arthritis Care & Research.

There is an increased risk for developing inflammatory arthritis among patients with hidradenitis suppurativa, according to a population-based cohort study published in JAMA Dermatology.

Approximately 66% of adults with psoriatic arthritis waited 6 months or more for their diagnosis after first seeking medical attention, with about 32.5% waiting 5 years or more, according survey findings published in BMC Rheumatology.

MAUI, HAWAII — Though approximately 25% of patients with psoriasis will eventually develop psoriatic arthritis, it remains unclear which patients will, according to a presentation here at Maui Derm for Dermatologists 2020.

Patients with psoriatic arthritis are more likely to achieve treatment targets, such as remission or low disease activity, with apremilast if they demonstrate moderate, compared with high, disease activity at baseline, according to data published in Arthritis Care & Research.

Although TNF inhibitor use was associated with an increased risk of serious infection among patients with psoriasis and self-reported psoriatic arthritis, recent data published in BMC Rheumatology found these differences were not statistically significant.

Adiposity — particularly central obesity — is associated with an increased risk for psoriatic arthritis, according to data published in Arthritis Care & Research.